Welcome to our dedicated page for Ventyx Biosciences news (Ticker: VTYX), a resource for investors and traders seeking the latest updates and insights on Ventyx Biosciences stock.
Ventyx Biosciences, Inc. news covers the company’s history as a Nasdaq-listed clinical-stage biopharmaceutical issuer developing oral small-molecule therapies for autoimmune, inflammatory, cardiovascular and neurodegenerative diseases. Recurring updates include NLRP3 inhibitor programs such as VTX2735 for recurrent pericarditis and VTX3232 for inflammation-related cardiovascular and neurodegenerative indications, as well as inflammatory bowel disease candidates tamuzimod (VTX002) and VTX958.
Company announcements also address clinical data, trial planning, advisory board changes, investor conference participation, operating and financial results, material agreements, shareholder voting matters and the completed acquisition that made Ventyx a wholly owned subsidiary of Eli Lilly and Company.
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Parkinson's disease.
The trial will enroll about ten patients for a 28-day open-label treatment period. Its primary endpoint is safety and tolerability, with additional measures including pharmacokinetics and relevant biomarkers in plasma and cerebrospinal fluid. Topline results are expected in 2025.
Ventyx Biosciences (Nasdaq: VTYX) has announced the departure of Martin Auster, M.D. from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the company's SVP of Finance, has been appointed as interim Principal Financial Officer and Principal Accounting Officer for SEC reporting purposes. Ventyx, a clinical-stage biopharmaceutical company focused on developing novel oral therapies for inflammatory diseases, has initiated a search for a new CFO.
CEO Raju Mohan, Ph.D., expressed gratitude for Dr. Auster's contributions over the past three years, including leading the company through its initial public offering, managing financial and governance matters, and supporting investor relations. Dr. Auster reciprocated, stating his pride in the company's accomplishments and wishing Ventyx future success.
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company developing novel oral therapies for inflammatory diseases, has announced its participation in two upcoming investor conferences:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA on September 4, 2024, from 11:00-11:35 AM ET.
2. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 6, 2024, from 1:05-1:40 PM ET.
Webcasts of the presentations will be available on the Ventyx website (www.ventyxbio.com) in the Investors and News section. Replays will be accessible for thirty days after the events.
Ventyx Biosciences (Nasdaq: VTYX) reported Q2 2024 financial results and corporate updates. Key highlights include:
1. Plans to initiate three Phase 2 trials in H2 2024: VTX3232 for obesity/cardiometabolic conditions and Parkinson's disease, and VTX2735 for recurrent pericarditis.
2. Appointment of Mark Forman, MD, PhD as Chief Medical Officer effective August 12, 2024.
3. Cash position of $279.7 million as of June 30, 2024, expected to fund operations into at least H2 2026.
4. Q2 2024 financial results: R&D expenses $27.8 million, G&A expenses $7.9 million, net loss $32.0 million.
5. Positive Phase 1 results for VTX3232 and Phase 2 results for VTX2735 in CAPS.
6. Seeking partnership for VTX002 Phase 3 trial in ulcerative colitis.
Ventyx Biosciences (Nasdaq: VTYX) announced results from the Phase 2 trial of VTX958 in Crohn's disease. The trial did not meet its primary endpoint of change in mean CDAI score from baseline to Week 12 due to a higher than anticipated placebo response. However, both VTX958 dose groups (225 mg and 300 mg twice daily) achieved nominal statistical significance on the key secondary endpoint of endoscopic response as measured by SES-CD.
The trial enrolled 109 participants and showed a dose-dependent treatment effect on endoscopic response. VTX958 was well-tolerated, with a safety profile consistent with previous trials. Despite these mixed results, Ventyx does not anticipate conducting additional clinical trials of VTX958 with internal resources. The company held $279.7 million in cash and equivalents as of June 30, 2024, which is expected to fund operations into at least the second half of 2026.
Ventyx Biosciences announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor, VTX3232. The study, conducted on diet-induced obesity (DIO) mice, showed that VTX3232 monotherapy led to reductions in body weight, body fat, food consumption, liver triglycerides, and fat deposits. Improvements in insulin resistance, cardiometabolic parameters, and systemic inflammation biomarkers were also noted. When combined with the GLP-1 receptor agonist semaglutide, VTX3232 exhibited additive effects, further reducing body weight, liver steatosis, and metabolic parameters compared to either treatment alone. Ventyx plans to initiate a Phase 2a trial of VTX3232 in obese participants with cardiovascular risk factors later this year.
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical firm, will participate in three upcoming investor conferences. The events are as follows: UBS Obesity Therapeutics Day on May 23, 2024, at 12:00-12:30 PM ET (virtual); Jefferies Global Healthcare Conference on June 6, 2024, at 11:00-11:25 AM ET in New York, NY; and Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami, FL. Webcasts for the UBS and Jefferies presentations will be accessible on the Ventyx website for 30 days post-event.
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company focused on developing novel oral therapies for inflammatory diseases, has appointed Matthew Moore as its new Chief Operating Officer, effective May 16, 2024.
Moore joins Ventyx with extensive experience in the biopharma industry, having previously served as the Chief Business Officer at Arcutis Biotherapeutics and held key roles at AbbVie, Allergan, Actavis, and Forest Labs.
In his new role, Moore will oversee corporate operations, business development, and strategy to advance Ventyx's pipeline of innovative oral therapies targeting unmet medical needs in inflammatory diseases.
Ventyx Biosciences, a clinical-stage biopharmaceutical company, announced financial results for Q1 2024, highlighting recent pipeline progress. With $302.6 million in cash, they plan to fund operations into H2 2026. Initiating Phase 2a trials of CNS-penetrant NLRP3 Inhibitor VTX3232 for Parkinson's disease and obesity. Positive results from Phase 1 trials supporting VTX3232 as a potential best-in-class treatment. Additionally, positive results from Phase 2 proof of concept trial of VTX2735 in patients with CAPS. Expecting to provide updates on future development in cardiovascular diseases. Positive Phase 2 results for VTX002 in ulcerative colitis and ongoing Phase 2 trial for VTX958 in Crohn's disease. Hosting a conference call to discuss financial results and corporate progress.
Ventyx Biosciences, Inc. (Nasdaq: VTYX) will report its first quarter 2024 financial results on May 9, 2024. The company focuses on developing novel oral therapies for inflammatory diseases with unmet medical needs. The conference call and webcast will discuss financial results, recent pipeline progress, and business updates.